Home > Insider Trading > Filing (0000950170-25-047761)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1463361	Unity Biotechnology Inc.	UBX	Pharmaceutical Preparations (2834)	264726035

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1850065	Hieu Alexander Nguyen	C/O Unity Biotechnology, Inc. 285 East Grand Avenue South San Francisco CA 94080	Clo And Head Of Ops	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.0001 Par Value	Disposition	2025-03-27	1,954	$1.16	22,605	No	4	S	Direct
Common Stock, $0.0001 Par Value	Acquisiton	2025-03-28	44,000	$0.00	66,605	No	4	A	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	A	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2025-03-28	73,000	$0.00	73,000	$1.67

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
73,000		2035-03-27	No	4	A	Direct

Footnotes

Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading instruction to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units.
Includes Restricted Stock Units ("RSUs") that vest over time measured from the grant date.
On January 30, 2024, the Board of Directors granted the Reporting Person 44,000 RSUs that vest in full upon the satisfaction of certain performance criteria, which were met on March 28, 2025.
Includes RSUs that vest over time measured from the grant date.
On January 30, 2024, the Board of Directors granted the Reporting Person an option to purchase 73,000 shares of common stock. The underlying shares vest and become exercisable pursuant to the following schedule: one half of the shares subject to the option vest upon the satisfaction of certain performance criteria, which were met on March 28, 2025, and the remaining shares subject to the option vest in 12 successive, equal monthly installments thereafter until fully vested, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.